A sharp increase in cases across parts of the world has followed the emergence of a newly identified COVID-19 variant, NB.1.8.1—nicknamed “Nimbus” or the “razor blade throat” variant. The variant earned its nickname due to the intense sore throat it reportedly causes, described by patients as feeling like swallowing razor blades. Medical professionals in the UK, India, and other countries have flagged this symptom as a prominent feature.
Where Is It Spreading?
According to the World Health Organization (WHO), the late-May surge in COVID-19 cases was most noticeable in the eastern Mediterranean, Southeast Asia, and western Pacific regions. As of mid-May, the Nimbus variant accounted for nearly 11% of sequenced samples worldwide. U.S. airport screenings also detected the variant in travelers arriving in California, Washington, Virginia, and New York from these affected regions.
Severity Remains Comparable to Other Variants
As reported by TOI, despite the sharp throat pain associated with Nimbus, experts report that the variant does not appear to cause more severe illness than previous strains. While some western Pacific countries have observed increased hospitalizations, the WHO stated there is currently no evidence that Nimbus leads to more critical disease.
Vaccines Continue to Offer Protection
Fortunately, existing COVID-19 vaccines effectively protect against the Nimbus variant. The WHO has classified it as a “variant under monitoring,” indicating that it poses a low global public health risk while they continue tracking its spread.
Controversy Over Vaccine Guidance
In a separate development, U.S. Health Secretary Robert F. Kennedy Jr. recently announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. However, public health experts quickly challenged this guidance, emphasizing the continued safety and benefits of vaccination for these groups.